Edwards Lifesciences price target raised to $88 from $83 at Piper Sandler

Piper Sandler analyst Adam Maeder raised the firm’s price target on Edwards Lifesciences to $88 from $83 and keeps a Neutral rating on the shares post the Q2 results. The analyst feels “incrementally better” about the company’s ability to deliver double-digit sales growth, but sees limited upside to the fiscal year guidance and says the stock’s current valuation levels are appropriate.